GLP-1 CollectiveCompounded GLP-1s
Cheaper, and not
the same thing.
People ask us about compounded semaglutide and tirzepatide constantly, because the prices are a fraction of the branded ones. We would rather tell you what they are and what the rules now say than leave you to work it out from advertising.
Compounded GLP-1 medications are not FDA approved
The FDA does not review compounded drugs for safety, effectiveness or manufacturing quality before they reach you. Approval applies to the branded products only. A compounded version of semaglutide or tirzepatide is a different preparation, made by a pharmacy, and nobody has evaluated that preparation the way the approved medication was evaluated. The GLP-1 Collective does not recommend, endorse, supply or arrange compounded medication of any kind.
Comparing prices
If you are going to look, look with your eyes open.
People do find lower prices through telehealth clinics, and pricing across those clinics is uneven and often hard to compare, with membership fees and dose-based increases that are not obvious on the first page. GLP Winner publishes side-by-side pricing for telehealth providers, including which compounding pharmacy each one uses and which providers work with insurance. We link it so you can compare openly and decide for yourself.
FAQ
What changed, and what it means for you.
During the shortages, federal law allowed pharmacies to compound copies of medications that were unavailable, and a large telehealth market grew up around that allowance. That allowance has ended.
The shortages were declared over
The FDA removed tirzepatide from its shortage list in late 2024 and semaglutide in early 2025, which returned both to the ordinary restrictions on compounding.
Copies are no longer permitted at scale
Outsourcing facilities had to stop compounding these products, and legal challenges to that did not succeed. A state-licensed pharmacy may still compound for an individual patient when the prescriber documents a clinically significant difference for that person, which is a much narrower situation than the market that existed in 2024.
The FDA has proposed going further
In 2026 the agency proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may use, finding no clinical need for them. The comment period closed in June 2026.
What that means for you
Availability from any particular seller can stop with little warning, and a supply you were relying on may not be there next month. That is worth planning for before you start, not after.
Is this the whole picture?
No. Compounding rules, court challenges and the products on offer all keep moving, and this page is updated periodically rather than continuously, so there may well be something newer than what is written here. Our policy tracker follows the changes as they are announced.